The effects of a bioavailable curcumin formulation on Alzheimer's disease pathologies: A potential risk for neuroinflammation
2024

Curcumin's Effects on Alzheimer's Disease in Mice

Sample size: 32 publication 10 minutes Evidence: moderate

Author Information

Author(s): Cade Shaun, Prestidge Clive, Zhou Xin‐Fu, Bobrovskaya Larisa

Primary Institution: University of South Australia

Hypothesis

Does a bioavailable curcumin formulation alter Alzheimer's disease pathologies in a mouse model?

Conclusion

The bioavailable curcumin formulation did not reduce amyloid plaques and may have aggravated neuroinflammation.

Supporting Evidence

  • The curcumin formulation did not change the number or size of amyloid plaques in the brain.
  • Curcumin increased GFAP protein levels, indicating potential neuroinflammation.
  • Previous studies showed curcumin's effectiveness in reducing amyloid plaques, but this study did not replicate those findings.

Takeaway

Researchers tested a special curcumin drink on mice with Alzheimer's, but it didn't help with the brain problems and might have made things worse.

Methodology

Mice were treated with a curcumin formulation, and their brains were analyzed for amyloid plaques and neuroinflammation.

Potential Biases

Potential bias due to the authors' involvement in the development of the curcumin formulation.

Limitations

The study focused mainly on amyloid pathology and did not assess cognitive performance.

Participant Demographics

Male and female APPswe/PS1dE9 mice were used as the Alzheimer's model.

Statistical Information

P-Value

p=0.0036

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1002/ibra.12187

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication